FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2579927051> ?p ?o ?g. }

• W2579927051 abstract "Pilocytic astrocytomas (PAs) are the most common pediatric central nervous system neoplasms. In the majority of cases these tumors are benign and receive favorable prognosis following gross total surgical resection. In patients with progressive or symptomatic tumors, aggressive surgical resection is generally not feasible, thus radiation or chemotherapy are accepted initial or adjuvant interventions. Due to serious long-lasting side-effects, radiation is limited in young children; therefore, chemotherapy is widely practiced as an adjuvant treatment for these patients. However, chemotherapy can promote the emergence of multidrug resistant tumor cells that are more malignant than those of the original tumor. CD133, a putative stem cell marker in normal tissue and malignant brain tumors, enhances multidrug resistant gene 1 (MDR1) expression following chemotherapy in adult malignant glioblastomas. This study examines the relationship between CD133 and MDR1 in pediatric PAs exposed to chemotherapy, with the goal of identifying therapeutic targets that manifest as a result of chemotherapy.Slides were obtained for 15 recurrent PAs, seven of which had received chemotherapy prior to surgical treatment for the recurrent tumor. These samples, as well as primary tumor tissue slides from the same patients were used to investigate CD133 and MDR1 expression via immunofluorescence. Archived frozen tissue samples from the same patients were used to examine CD133, MDR1 and PI3K-Akt-NF-κB signaling mediators, via western blot. Two drug resistant pediatric PA cell lines Res186 and Res199 were also used to evaluate the role of CD133 on cell response to cytotoxic therapy.CD133 and MDR1 were co-expressed and their expression was elevated in recurrent PAs from patients that had received chemotherapy, compared to patients that had not received chemotherapy. PI3K-Akt-NF-κB signaling mediator expression was also elevated in recurrent, chemotherapy-treated PA. Suppressing CD133 expression with siCD133 decreased levels of PI3K-Akt-NF-κB signaling mediators and MDR1, while increasing cell chemosensitivity, as indicated by quantification of apoptotic cells following chemotherapy.CD133 contributes to multidrug resistance by regulating MDR1 levels via the PI3K-Akt-NF-κB signal pathway not only in adult glioblastomas, but also in pediatric PAs. Targeting CD133, adjuvant to conventional chemotherapy may improve outcomes for children with recurrent PA." @default.
• W2579927051 created "2017-02-03" @default.
• W2579927051 creator A5003799255 @default.
• W2579927051 creator A5008888430 @default.
• W2579927051 creator A5009821621 @default.
• W2579927051 creator A5022132137 @default.
• W2579927051 creator A5023971218 @default.
• W2579927051 creator A5037916968 @default.
• W2579927051 creator A5066373582 @default.
• W2579927051 creator A5075628883 @default.
• W2579927051 creator A5087119700 @default.
• W2579927051 date "2017-01-31" @default.
• W2579927051 modified "2023-10-17" @default.
• W2579927051 title "Targeting CD133 improves chemotherapeutic efficacy of recurrent pediatric pilocytic astrocytoma following prolonged chemotherapy" @default.
• W2579927051 cites W1493594926 @default.
• W2579927051 cites W1578072993 @default.
• W2579927051 cites W1582496453 @default.
• W2579927051 cites W1774630295 @default.
• W2579927051 cites W1889670825 @default.
• W2579927051 cites W1971082528 @default.
• W2579927051 cites W2001544973 @default.
• W2579927051 cites W2006434892 @default.
• W2579927051 cites W2014935530 @default.
• W2579927051 cites W2015610520 @default.
• W2579927051 cites W2021448795 @default.
• W2579927051 cites W2023846533 @default.
• W2579927051 cites W2039994380 @default.
• W2579927051 cites W2049423881 @default.
• W2579927051 cites W2054229754 @default.
• W2579927051 cites W2058845478 @default.
• W2579927051 cites W2060158959 @default.
• W2579927051 cites W2060551076 @default.
• W2579927051 cites W2061521956 @default.
• W2579927051 cites W2062069198 @default.
• W2579927051 cites W2073847012 @default.
• W2579927051 cites W2074099687 @default.
• W2579927051 cites W2074803927 @default.
• W2579927051 cites W2082132576 @default.
• W2579927051 cites W2100130667 @default.
• W2579927051 cites W2106105815 @default.
• W2579927051 cites W2106689678 @default.
• W2579927051 cites W2119449786 @default.
• W2579927051 cites W2124482905 @default.
• W2579927051 cites W2135923360 @default.
• W2579927051 cites W2140323094 @default.
• W2579927051 cites W2147051337 @default.
• W2579927051 cites W2147447567 @default.
• W2579927051 cites W2151113527 @default.
• W2579927051 cites W2151891352 @default.
• W2579927051 cites W2153424791 @default.
• W2579927051 cites W2155880350 @default.
• W2579927051 cites W2158293719 @default.
• W2579927051 cites W2158920119 @default.
• W2579927051 cites W2158989051 @default.
• W2579927051 cites W2165551601 @default.
• W2579927051 cites W2167650288 @default.
• W2579927051 cites W2403633080 @default.
• W2579927051 cites W73010523 @default.
• W2579927051 doi "https://doi.org/10.1186/s12943-017-0593-z" @default.
• W2579927051 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5282778" @default.
• W2579927051 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28137267" @default.
• W2579927051 hasPublicationYear "2017" @default.
• W2579927051 type Work @default.
• W2579927051 sameAs 2579927051 @default.
• W2579927051 citedByCount "18" @default.
• W2579927051 countsByYear W25799270512017 @default.
• W2579927051 countsByYear W25799270512019 @default.
• W2579927051 countsByYear W25799270512020 @default.
• W2579927051 countsByYear W25799270512021 @default.
• W2579927051 countsByYear W25799270512022 @default.
• W2579927051 countsByYear W25799270512023 @default.
• W2579927051 crossrefType "journal-article" @default.
• W2579927051 hasAuthorship W2579927051A5003799255 @default.
• W2579927051 hasAuthorship W2579927051A5008888430 @default.
• W2579927051 hasAuthorship W2579927051A5009821621 @default.
• W2579927051 hasAuthorship W2579927051A5022132137 @default.
• W2579927051 hasAuthorship W2579927051A5023971218 @default.
• W2579927051 hasAuthorship W2579927051A5037916968 @default.
• W2579927051 hasAuthorship W2579927051A5066373582 @default.
• W2579927051 hasAuthorship W2579927051A5075628883 @default.
• W2579927051 hasAuthorship W2579927051A5087119700 @default.
• W2579927051 hasBestOaLocation W25799270511 @default.
• W2579927051 hasConcept C126322002 @default.
• W2579927051 hasConcept C142724271 @default.
• W2579927051 hasConcept C143998085 @default.
• W2579927051 hasConcept C2776694085 @default.
• W2579927051 hasConcept C2777722931 @default.
• W2579927051 hasConcept C2778227246 @default.
• W2579927051 hasConcept C2778880634 @default.
• W2579927051 hasConcept C28328180 @default.
• W2579927051 hasConcept C502942594 @default.
• W2579927051 hasConcept C509974204 @default.
• W2579927051 hasConcept C54355233 @default.
• W2579927051 hasConcept C71924100 @default.
• W2579927051 hasConcept C86803240 @default.
• W2579927051 hasConceptScore W2579927051C126322002 @default.
• W2579927051 hasConceptScore W2579927051C142724271 @default.
• W2579927051 hasConceptScore W2579927051C143998085 @default.
• W2579927051 hasConceptScore W2579927051C2776694085 @default.
• W2579927051 hasConceptScore W2579927051C2777722931 @default.

• next